Publications by authors named "E Vinet"
Article Synopsis
- This study examined how the use of immunosuppressants, immunomodulators, and biologics among pregnant women with autoimmune diseases changed over time, comparing their usage before, during, and after pregnancy.
- It used data from the Quebec Pregnancy Cohort (1998-2015) to analyze trends and discontinuation of these treatments during pregnancy, identifying various factors influencing the decision to stop medication.
- Findings showed an increase in pre-pregnancy use of these medications, but a notable decline during pregnancy, highlighting the complexity of managing autoimmune conditions while considering fetal health.
Objective: To assess the association of trimethoprim sulfamethoxazole (TMP-SMX) prophylaxis with serious infections in rituximab-treated patients with granulomatosis with polyangiitis (GPA).
Methods: This retrospective cohort study included adults with GPA (2011-2020) within the United States Merative™ Marketscan® Research Databases with ≥6 months enrolment prior to first (index) rituximab treatment. We defined TMP-SMX prophylaxis as a ≥28-day prescription dispensed after or overlapping the index date.
Tumour necrosis factor inhibitors (TNFi) are commonly used to treat patients with chronic inflammatory diseases, and function by inhibiting the pro-inflammatory cytokine tumour necrosis factor-α (TNF-α). Although beneficial in reducing disease activity, they are associated with an increased risk of serious infections. Data on the risk of serious infections associated with TNFi use during the reproductive years, particularly in pregnancy, are limited.
View Article and Find Full Text PDF